MNPR
Monopar Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.96 / 10
Outperform
Analyst consensus is strongly positive with a 100% Strong Buy rating from three analysts. Money flow is healthy (7.86/10), showing consistent inflows across all size brackets, which supports the bullish sentiment despite neutral technicals.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-02-02
InstitutionBTIG
Times predicted5
Historical Win Rate60.0%
Is money flowing into or out of MNPR?
- MNPR holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.96/10 (Outperform).
